Pancreatic Cancer Research

ResearcherFukushima Medical UniversityActive in the last 2 years

Hajime Yamazaki

Matched on ORCID iD 0000-0002-9034-4370; OpenAlex author ID A5007781775, A5135360330, A5154096507. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 2 papers · 2026: 2 papers

Papers 7

  1. Nonlinear Modeling Reveals Novel Associations Between Genetically Predicted Protein Levels and Pancreatic Cancer Risk. Co-author DOI 10.1002/mc.70135↗
  2. Early Detection of Pancreatic Adenocarcinoma Using Triple-phase contrast-enhanced Computed Tomography: A Case-control Study. Co-author DOI 10.1097/mpa.0000000000002712↗
  3. Serum Mac2-binding protein glycosylated isomer (M2BPGi) as a prognostic biomarker in pancreatic ductal adenocarcinoma: iCAFs-derived M2BPGi drives tumor invasi… Co-author DOI 10.1007/s00535-024-02195-8↗
  4. Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclit… Co-author DOI 10.1016/j.esmogo.2025.100221↗
  5. Evidence for a causal link between intra-pancreatic fat deposition and pancreatic cancer: A prospective cohort and Mendelian randomization study. Co-author DOI 10.1016/j.xcrm.2023.101391↗
  6. Evidence for a causal link between intra-pancreatic fat deposition and pancreatic cancer: A prospective cohort and Mendelian randomization study. Co-author DOI 10.1016/j.xcrm.2024.101842↗
  7. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderl… Co-author DOI 10.1016/j.ijrobp.2019.07.004↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Samantha A. Streicher · 2 shared papers, 2024 · strength 0.40
  2. Brian Z. Huang · 2 shared papers, 2024 · strength 0.40
  3. Veronica Wendy Setiawan · 2 shared papers, 2024 · strength 0.40
  4. Lang Wu · 2 shared papers, 2024 · strength 0.40
  5. Heinz‐Josef Lenz · 2 shared papers, 2024 · strength 0.40
  6. Steven R. Grossman · 2 shared papers, 2024 · strength 0.40
  7. Tsuyoshi Hayashi · 2 shared papers, 2019–2026 · strength 0.36
  8. Akio Katanuma · 2 shared papers, 2019–2026 · strength 0.36
  9. Jingjing Zhu · 1 shared paper, 2026 · strength 0.33
  10. Lang Wu · 1 shared paper, 2026 · strength 0.33
  11. Omeed Moaven · 1 shared paper, 2026 · strength 0.33
  12. Yasuo Sakurai · 1 shared paper, 2026 · strength 0.29
  13. Naotaka Kugiyama · 1 shared paper, 2025 · strength 0.21
  14. Hiromitsu Hayashi · 1 shared paper, 2025 · strength 0.21
  15. Yasuhito Tanaka · 1 shared paper, 2025 · strength 0.21
  16. Katsuya Nagaoka · 1 shared paper, 2025 · strength 0.21
  17. Takatsugu Ishimoto · 1 shared paper, 2025 · strength 0.21
  18. Makoto Sugimori · 1 shared paper, 2025 · strength 0.21
  19. Masanori Oshi · 1 shared paper, 2025 · strength 0.21
  20. Manabu Morimoto · 1 shared paper, 2025 · strength 0.21
  21. Yoshimasa Suzuki · 1 shared paper, 2025 · strength 0.21
  22. Shin Maeda · 1 shared paper, 2025 · strength 0.21
  23. Makoto Yoshida · 1 shared paper, 2019 · strength 0.08
  24. Yasutoshi Kimura · 1 shared paper, 2019 · strength 0.08
  25. Norio Katoh · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.